Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) Return on Sales (2016 - 2025)

BioCorRx's Return on Sales history spans 15 years, with the latest figure at 1.27% for Q3 2025.

  • For Q3 2025, Return on Sales rose 18496.0% year-over-year to 1.27%; the TTM value through Sep 2025 reached 4.5%, up 18174.0%, while the annual FY2024 figure was 679.99%, 63770.0% down from the prior year.
  • Return on Sales for Q3 2025 was 1.27% at BioCorRx, up from 7.73% in the prior quarter.
  • Across five years, Return on Sales topped out at 1.27% in Q3 2025 and bottomed at 679.99% in Q4 2024.
  • The 5-year median for Return on Sales is 67.56% (2021), against an average of 124.02%.
  • The largest annual shift saw Return on Sales plummeted -62877bps in 2024 before it surged 33553bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 88.39% in 2021, then surged by 84bps to 14.08% in 2022, then crashed by -264bps to 51.22% in 2023, then crashed by -1228bps to 679.99% in 2024, then surged by 100bps to 1.27% in 2025.
  • Per Business Quant, the three most recent readings for BICX's Return on Sales are 1.27% (Q3 2025), 7.73% (Q2 2025), and 6.31% (Q1 2025).